NAPSRx

The U.S. Food and Drug Administration’s (FDA) meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee, and the Drug Safety and Risk Management Advisory Committee has decided to support the approval of the benefit/risk profile of Sprout...

The U.S. Food and Drug Administration (FDA) has approved Pfizer’s RAPAMUNE® (sirolimus) making it the first approved therapy to treat lymphangioleiomyomatosis (LAM), a rare disease that affects the lungs, kidneys and the lymphatic system, which tends...

Valeant Pharmaceutical’s wholly owned subsidiary, Salix Pharmaceuticals, Inc received approval from the U.S. Food and Drug Administration (FDA) for Xifaxan® 550 mg to treat IBS-D (Irritable Bowel Syndrome with Diarrhea) in adults.

Johnson & Johnson (Janssen) plans to file regulatory approvals for 10 new products between 2014 and 2019, each with the potential to accumulate $1 billion in revenue plus 40 line extensions of existing and new medicines.

In a robust deal worth $8.05 billion, Endo Pharmaceuticals will acquire privately-held Par Pharmaceutical Holdings from TPG.

Baxter is ready to expand its oncology segment by acquiring Oncaspar® (pegaspargase) product portfolio from Sigma-Tau Finanziaria S.p.A for USD $900 million.

The investigational drug venetoclax has been granted Breakthrough Therapy Designation from the U.S.

Teva Pharmaceuticals has acquired Auspex Pharmaceuticals, Inc for all of the outstanding shares of common stock of Auspex at $101.00 per share in cash, totaling approximately $3.2 billion in enterprise value and approximately $3.5 billion in equity...

Isis Pharmaceuticals has entered into an agreement with Bayer Healthcare to commercialize and develop ISIS-FXIRx for the prevention of thrombosis.

On April 29, 2015, the U.S Food and Drug Administration (FDA) approved KYBELLA (deoxycholic acid) Injection manufactured by Kythera Biopharmaceuticals to improve Submental Fullness, or “Double Chin”.